Adjuvanted rush immunotherapy using CpG oligodeoxynucleotides in experimental feline allergic asthma.
Allergic asthma is driven by relative overexpression of Th2 cell-derived cytokines in response to aeroallergens. In independent studies, both allergen-specific rush immunotherapy (RIT) and CpG oligodeoxynucleotides (ODN) showed promise in blunting eosinophilic inflammation in a model of feline allergic asthma. We hypothesized that RIT using allergen and CpG ODN would work synergistically to dampen the asthmatic phenotype in experimentally asthmatic cats. Twelve cats with asthma induced using Bermuda grass allergen (BGA) were studied. Of these, six were administered adjuvanted BGA RIT using CpG ODN #2142; six were administered placebo (saline) RIT and later crossed over to adjuvanted RIT. Over 2 days, subcutaneous CpG ODN (0.5ng/kg) with BGA (increasing doses every 2h from 20 to 200microg) was administered. Adverse events were recorded and compared with historical controls. Percentage of eosinophils in bronchoalveolar lavage fluid (BALF), % peripheral CD4+CD25+ T regulatory cells (Tregs), lymphocyte proliferation in response to ConA, and cytokine concentrations in BALF were measured over 2 months. Group mean BALF % eosinophils for the adjuvanted RIT cats were significantly lower at week 1 and month 1 (p=0.03 for both), and marginally significantly lower at month 2 (p=0.09) compared with placebo RIT cats. By the end of the study, 8/12 treated cats had BALF % eosinophils within the reference range for healthy cats. Adjuvanted RIT, but not placebo RIT, cats had significant decreases in the ConA stimulation index over time (p=0.05). BALF IL-4 concentrations were significantly higher at week 1 in adjuvanted RIT cats compared with baseline and month 2, and also with placebo RIT cats at week 1. No significant differences were detected between treatments or over time for IL-10 or IFN-gamma concentrations in BALF or for %Tregs cells in peripheral blood. Adjuvanted RIT using CpG ODN in experimental feline asthma dampens eosinophilic airway inflammation. Adverse effects associated with adjuvanted RIT were less severe compared with a historical, non-adjuvanted RIT protocol. The exact mechanism(s) by which adjuvanted RIT alters the aberrant allergic immune response were not elucidated in this study.
Reinero
Carol R
CR
Department of Veterinary Medicine and Surgery, University of Missouri-Columbia, Columbia, MO 65211, USA. reineroc@missouri.edu
Cohn
Leah A
LA
Delgado
Cherlene
C
Spinka
Christine M
CM
Schooley
Elizabeth K
EK
DeClue
Amy E
AE
D000818:Animals; D001249:Asthma / Q000276:immunology / Q000628:therapy / Q000662:veterinary*; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology / Q000276:immunology; D002371:Cat Diseases / Q000276:immunology / Q000628:therapy*; D002415:Cats; D031744:Cynodon / Q000276:immunology*; D003888:Desensitization, Immunologic / Q000379:methods / Q000662:veterinary*; D004797:Enzyme-Linked Immunosorbent Assay / Q000662:veterinary; D004804:Eosinophils / Q000276:immunology; D005434:Flow Cytometry / Q000662:veterinary; D007371:Interferon-gamma / Q000378:metabolism; D016753:Interleukin-10 / Q000378:metabolism; D015847:Interleukin-4 / Q000378:metabolism; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
C408982:CPG-oligonucleotide; D009838:Oligodeoxyribonucleotides; D016753:Interleukin-10; D015847:Interleukin-4; D007371:Interferon-gamma